
Vidac Pharma Receives 'Buy' Rating and Increased Valuation from Sphene Capital, Underscoring Strong Growth Prospects
Sphene Capital Cites Strong Clinical Pipeline and Unique Approach to Tumor Microenvironment Disruption Vidac Pharma Plc (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, June 25, 2025 /EINPresswire.com/ -- Vidac Pharma Plc, a …